1
Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.
2
Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.
Discover the infinite power of partnership to drive scientific discovery
Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.
We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.
Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.
This post explores applications of genetically engineered organoids and cell lines to expand and accelerate anti-cancer drug discovery and development. We first provide a brief overview of two major methods that are used to develop engineered organoids/cell lines (i.e., lentiviral transduction and PiggyBac), followed by typical workflows for generating these models. Several case studies are presented to showcase their application for target validation and in vitro /in vivo efficacy studies.
Drug development is a lengthy, risky, and costly endeavor with high candidate attrition. Attrition rates for anticancer agents are much higher than in other therapeutic categories. Only 5% of them are estimated to reach the clinical stage. This very high rate has been attributed in part to the poor translatability of current preclinical data.
Major advances in breast cancer treatment have significantly improved survival rates, but metastatic disease continues to be the leading cause of breast cancer-related deaths. Developing novel therapies for metastatic breast cancer requires preclinical breast cancer models that better-recapitulate important clinical features of the disease, including metastasis.
The need for more clinically relevant preclinical models has been identified as one of the areas that can help reduce the high attrition rate observed for anticancer drugs. Better models, such as Hubrecht Organoid Technology (HUB) tumor organoids, can drive better decisions in drug discovery by identifying agents that will have the best chances of succeeding in clinical trials. In this post we explore the value of “living” tumor organoid biobanks for identifying anticancer agents with improved clinical relevance.
